Andrea Haegebarth

Berlin, BE 13353, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.

Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.

Journal: Journal of medicinal chemistry

Published: October 26, 2021

Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.

Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.

Journal: SLAS discovery : advancing life sciences R & D

Published: June 22, 2021

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: December 16, 2020

Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.

Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.

Journal: Cell reports

Published: September 23, 2020

Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.

Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.

Journal: Cancers

Published: December 12, 2019

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.

Journal: Haematologica

Published: September 09, 2019

SLC25A32 sustains cancer cell proliferation by regulating flavin adenine nucleotide (FAD) metabolism.

SLC25A32 sustains cancer cell proliferation by regulating flavin adenine nucleotide (FAD) metabolism.

Journal: Oncotarget

Published: August 12, 2019

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.

Journal: Journal of hematology & oncology

Published: March 29, 2019

Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.

Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.

Journal: Journal of medicinal chemistry

Published: December 20, 2018

Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.

Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis.

Journal: Journal of hepatology

Published: December 03, 2018

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.

The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies.

Journal: Leukemia

Published: October 25, 2018

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Journal: Molecular cancer therapeutics

Published: December 18, 2017

Showing 1-12 of 21

Last Updated: 09/26/2026